DreaMed Diabetes

Company profile

About DreaMed Diabetes

DreaMed Diabetes is a global leader in personalized diabetes treatment optimization, founded in 2014 by a visionary group of leading endocrinologists, engineers, and data scientists. The company pioneered the first artificial pancreas technology and became the world's first company to receive FDA clearance for a smart algorithm that provides personalized treatment recommendations. DreaMed's mission is to transform diabetes management for everyone, everywhere, by closing the gap between rising patient demand and limited specialist availability through harnessing medical data and delivering personalized treatment. Their cutting-edge technology translates complex glucose and insulin data into expert-level treatment guidance. The company's flagship product, MODI, is the first FDA-cleared solution to use continuous glucose monitoring (CGM) data to automatically optimize insulin dosing for people with type 2 diabetes across both basal-only and multiple daily injection regimens. MODI delivers personalized dose recommendations directly to patients through a mobile application, without requiring healthcare provider review or approval for each adjustment. This brings automated insulin optimization to the 85% of insulin users who rely on injections and have historically had fewer options for automated dosing support. DreaMed also offers endo.digital, a decision-support platform for healthcare providers managing patients with type 1 and type 2 diabetes. The company operates under stringent quality management systems and adheres to ISO 27001, GDPR, and HIPAA standards, with SOC 2 certification.

Company description · DreaMed Diabetes official website

Mission. Transforming diabetes management, for everyone – everywhere.